A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Induction and Maintenance Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Japanese Subjects With Eosinophilic Gastroenteritis
Latest Information Update: 12 May 2025
At a glance
- Drugs Cendakimab (Primary)
- Indications Eosinophilic gastroenteritis
- Focus Registrational; Therapeutic Use
- Sponsors Celgene Corporation
Most Recent Events
- 04 May 2025 Planned End Date changed from 19 Nov 2026 to 11 Sep 2025.
- 13 Feb 2025 Planned number of patients changed from 45 to 48.
- 09 Jan 2024 Status changed from recruiting to active, no longer recruiting.